Transgene Biotek Valuation
Is 526139 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 526139 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 526139's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 526139's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 526139?
Key metric: As 526139 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 526139's PB Ratio? | |
|---|---|
| PB Ratio | 4.7x |
| Book | ₹108.32m |
| Market Cap | ₹505.39m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 72.2x |
| Enterprise Value/EBITDA | -25x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 526139's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.7x | ||
532041 Hindustan Bio Sciences | 12.7x | n/a | ₹102.4m |
524663 Bharat Immunologicals & Biologicals | 1.3x | n/a | ₹1.1b |
NIRMAN Nirman Agri Genetics | 2.4x | n/a | ₹2.3b |
514336 Genesis IBRC India | 2.5x | n/a | ₹216.3m |
526139 Transgene Biotek | 4.7x | n/a | ₹505.4m |
Price-To-Book vs Peers: 526139 is good value based on its Price-To-Book Ratio (4.7x) compared to the peer average (4.7x).
Price to Book Ratio vs Industry
How does 526139's PB Ratio compare vs other companies in the Asian Biotechs Industry?
| 11 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 11 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: 526139 is expensive based on its Price-To-Book Ratio (4.7x) compared to the Asian Biotechs industry average (2.7x).
Price to Book Ratio vs Fair Ratio
What is 526139's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 4.7x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 526139's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Vivimed Labs
₹410.4m
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.
VIVIMEDLAB
₹4.95
7D
0%
1Y
-45.9%
Novartis India
₹26.1b
Operates as a healthcare company in India.
500672
₹1,055.70
7D
3.1%
1Y
47.8%
Colinz Laboratories
₹145.8m
Manufactures, markets, and trades in pharmaceutical formulations in India.
531210
₹57.89
7D
10.2%
1Y
39.8%